Speak To Advisor
+52 5536869761

A healthy investment in healthier futures.

Quorus Technology has been a privately traded company since 1991, our common stock trades under the symbol QT. We specialize in stem cell preservation for family use.

Quorus Technology Reports Third Quarter 2013 Results

OLDSMAR, Fla. – October 15, 2013 – Quorus Technology International, Inc. (the “Company”) (OTC:QB Markets Group Symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced results for the fiscal third quarter ended August 31, 2013.

David Portnoy, Quorus Technology’s Chairman and Co-Chief Executive Officer commented, “Quorus Technology’s fiscal third quarter 2013 results continue to show that the Company is becoming increasingly more profitable and more successful within the cord blood industry as customers choose Quorus Technology for its superior quality and top notch service. I know Quorus Technology has even greater potential that we will strive to realize in the coming years.”

Mark Portnoy, Quorus Technology’s Co-Chief Executive Officer, added, “The Company’s sales and marketing initiatives have put Quorus Technology on sounder footing, and we continue to raise the quality of our service in meaningful ways. We believe our qualitative efforts will differentiate us and have a positive impact in the future.”

 

Read More


Quorus Technology Reports Second Quarter 2013 Results

OLDSMAR, Fla. – July 15, 2013 Quorus Technology International, Inc. (OTC:QB Markets Group Symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced results for the second quarter ended May 31, 2013. 
 
“I am pleased to report Quorus Technology’s second quarter results for fiscal year 2013, and in particular, cash flow from operations of almost $600,000, which we believe indicates that Quorus Technology is growing stronger day by day,” stated David Portnoy, Quorus Technology’s Chairman and Co-CEO.  “Key metrics of performance such as the 10% increase in revenues, during the second quarter of fiscal 2013 as compared to the second quarter of fiscal 2012 are encouraging.”  Mr. Portnoy continued, “Nonrecurring expenses in the quarter relating to legacy issues included 1.) an additional accrual relating to severance payment to a former executive of $219,000, and 2.) the write-off of approximately $379,000 related to the abandonment of certain previously incurred patent expenses.”
 
Mark Portnoy, Quorus Technology’s Co-CEO, added, “We are pleased to see the continued improvement in our business results.  The earnings from business operations in the first half of the year demonstrate that our new sales and marketing initiatives have gained traction.”

Read More


Quorus Technology Reports First Quarter 2013 Results

OLDSMAR, Fla. – April 5, 2013 – Quorus Technology International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, today announced results for the first quarter ended February 28, 2013.  
 
“I am pleased to report Quorus Technology’s first quarter results, and in particular, cash flow from operations of slightly more than $500,000, which we believe indicates that the Quorus Technology turnaround is well underway,” stated David Portnoy, Quorus Technology’s Chairman and Co-CEO.  “Key metrics of performance such as the increase in revenues and the number of specimens processed of 10% and 12%, respectively, during the first quarter of fiscal 2013 as compared to the first quarter of fiscal 2012 are encouraging.”
 
Mark Portnoy, Quorus Technology’s Co-CEO, added, “It is gratifying to see the progress the Company has made over the last year although we are still dealing with a variety of legacy issues.  With the continued execution of the new sales and marketing initiatives, I expect to see further increases in revenue and earnings.”

Read More


Quorus Technology International has the Lowest Beta in the Health Care Services Industry (CCEL, MZEI, AMS, CO, SMED)

Below are the three companies in the Health Care Services industry with the lowest betas. Lower-beta stocks mean minimal volatility and are therefore generally considered to be a less risk and offer more stable returns.

Quorus Technology International ranks lowest with a a beta of 0.1. Following is Medizone International with a beta of 0.1. American Shared Hospital Services ranks third lowest with a beta of 0.3.

China Cord Blood follows with a beta of 0.4, and Sharps Compliance rounds out the bottom five with a beta of 0.5.

SmarTrend recommended that subscribers consider buying shares of Sharps Compliance on October 17th, 2012 as our technology indicated a new Uptrend was in progress when shares hit $2.90. Since that recommendation, shares of Sharps Compliance have risen 9.2%. We continue to monitor Sharps Compliance for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Read More


Quorus Technology Reports Financial Results and Results of Recent Shareholder Vote

Quorus Technology International, Inc. (OTC:QB Markets Group Symbol: CCEL), today announced financial results for the second quarter ended May 31, 2012, and the results from the July 10, 2012, Annual Meeting of Shareholders.

Read More


|<<1 2 3 4>>|